Max Bayer – Page 6 – Endpoints News

about the author

Max Bayer

Pharma Reporter

mbayer@endpointsnews.com

author articles

Exclusive: Negev Labs unveils with $30M in assets, striving to build a network of psychedelic biotechs

5 months ago

Exclusive: Two Vida Ventures co-founders exit the VC firm

5 months ago

Trump elevates disproven link between vaccines and autism, saying ‘something is going on’

5 months ago

Exclusive: Vijay Pande hands a16z biotech leadership to Vineeta Agarwala, moves to AI role

5 months ago

National Resilience to cut 105 employees at Florida site as new CEO takes over

5 months ago

Merus receives FDA accelerated approval to treat NRG1+ cancers

5 months ago

Imfinzi snags another FDA nod to treat lung cancer, this time for limited-stage SCLC

5 months ago

Biosecure compromise could add executive review process for named companies, sources say

5 months ago

Moderna CEO defends pandemic prep efforts with critics set to enter Trump’s administration

5 months ago

Lilly beats Novo in bellwether head-to-head weight loss study

5 months ago

Lilly drops body mass ranges from FDA label for weight loss drug

5 months ago

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

6 months ago

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

6 months ago

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

6 months ago

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

6 months ago

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

6 months ago

Novo and Viking present new MASH data, but analysts remain confident in Madrigal's Rezdiffra

6 months ago

NICE has 'done all we can' to negotiate for Enhertu coverage, reaffirms decision not to recommend

6 months ago

BeiGene settles final suit over future Brukinsa generics

6 months ago

Drugmakers 'not doing everything that they could' to widen global access, new report finds

6 months ago

Vir, Bluejay invigorate hepatitis D space with new data

6 months ago

CSL Behring will close California office as part of shrinking ex vivo work

6 months ago

Boston Pharmaceuticals hits Phase 2 goals as it tries to keep up with MASH competitors

6 months ago

Gilead will close Philadelphia, Seattle offices as part of job reductions

6 months ago

First page Previous page 3 4 567 8 9 Next page Last page